Twitter Updates

    follow me on Twitter

    My Profile

    • EXPERTISE -
      Authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; issues and crisis management. Frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!

    About This Blog

    • Eye on FDA is published by Mark Senak of Fleishman-Hillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of Fleishman-Hillard or its clients.

    My Favorite Dogs

    • January20063_005
      Nick and Nora

    Stats

    • eXTReMe Tracker

    Eye on FDA edrugsearch blog ranking

    • Healthcare 100

    Syndication

    « Blink! | Main | The Bio Conference and the FDA Survey »

    April 17, 2006

    TrackBack

    TrackBack URL for this entry:
    http://www.typepad.com/services/trackback/6a00d83451bf5969e200d83427890353ef

    Listed below are links to weblogs that reference Avoiding a Crisis in Communications during a Medical Product Crisis:

    » Product Issues and Recalls - How to Handle from The Laszlo Letter
    As you may know by now, Bausch Lomb has run into a problem related to its product ReNu® with MoistureLoc® potentially causing fusarium keratitis in contact lens wearers. The company has asked pharmacies to temporarily take this product off the [Read More]

    Comments

    George Laszlo

    This certainly is a timely topic and there is a lot at stake for Bausch & Lomb. No sooner than they made an announcement, the pundits came out of the woodwork to say how well or badly they are handling the situation.

    On the negative side, one journalist faulted B&L for saying that their products are safe. This implied that there was nothing wrong with the product. The journalist went on to say that B&L should never have said this and show some responsibility. After all, how could they know so quickly that their product was indeed OK?

    I think the steps you outline may or may not have prevented this type of response. Using outside help may have brought a voice to the table and recommended some different wording that conveyed flexibility rather than intransigence. On the other hand, it is very hard to predict how anyting one says will be interpreted. All the more reason to weigh your words carefully and, in cases like this, get input from many sources before you go public.

    Verify your Comment

    Previewing your Comment

    This is only a preview. Your comment has not yet been posted.

    Working...
    Your comment could not be posted. Error type:
    Your comment has been posted. Post another comment

    The letters and numbers you entered did not match the image. Please try again.

    As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

    Having trouble reading this image? View an alternate.

    Working...

    Post a comment

    Subscribe / Email Me

    Enter your email address:

    Delivered by FeedBurner

    Search

    • Google

      WWW
      eyeonfda.com

    September 2010

    Sun Mon Tue Wed Thu Fri Sat
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30